Skip to content

Opening book details…

About this Medicine article

1330: Brigatinib efficacy and safety in patients (Pts) with anaplastic lymphoma kinase (ALK)-positive (ALK+) non-small cell lung cancer (NSCLC) in a phase 1/2 trial by Rosell, R.; Gettinger, S.N.; Bazhenova, L.A.; Langer, C.J.; Salgia, R.; Shaw, A.T.; Narasimhan, N.I.; Dorer, D.J.; Kerstein, D.; Camidge, D.R. is a Medicine article available to read on EtoBox.

It is typically read by researchers, students, and practitioners in Medicine.

Author
Rosell, R.; Gettinger, S.N.; Bazhenova, L.A.; Langer, C.J.; Salgia, R.; Shaw, A.T.; Narasimhan, N.I.; Dorer, D.J.; Kerstein, D.; Camidge, D.R.
Publisher
Elsevier ; Elsevier Inc.; Elsevier BV (ISSN 1556-1380)
Published
2016
Language
EN
Field
Medicine (Health Sciences)

More by Rosell, R.; Gettinger, S.N.; Bazhenova, L.A.; Langer, C.J.; Salgia, R.; Shaw, A.T.; Narasimhan, N.I.; Dorer, D.J.; Kerstein, D.; Camidge, D.R.

Browse all works by Rosell, R.; Gettinger, S.N.; Bazhenova, L.A.; Langer, C.J.; Salgia, R.; Shaw, A.T.; Narasimhan, N.I.; Dorer, D.J.; Kerstein, D.; Camidge, D.R.